Monte Rosa Therapeutics (NASDAQ:GLUE) Earns Outperform Rating from Analysts at Lifesci Capital
Lifesci Capital assumed coverage on shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) in a research report issued to clients and investors on Wednesday, Marketbeat reports. The brokerage set an “outperform” rating and a $19.00 price target on the stock. Lifesci Capital’s target price suggests a potential upside of 205.96% from the stock’s […]
Lifesci Capital assumed coverage on shares of Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) in a research report issued to clients and investors on Wednesday, Marketbeat reports. The brokerage set an “outperform” rating and a $19.00 price target on the stock. Lifesci Capital’s target price suggests a potential upside of 205.96% from the stock’s […]
